Actuate Therapeutics, Inc. (ACTU)
Nasdaq: ACTU · Pharmaceutical Preparations · Fort Worth, TX · filing with the SEC since 2015
Who owns Actuate Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
Aaron G.L. Fletcher holds 49.8% of Common Stock, par value $0.000001 per share, as its SCHEDULE 13D/A filed Jun 30, 2025 says.
Directors and officers
29
report now, of 39 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Aaron G.L. Fletcher
SCHEDULE 13D/A · filed Jun 30, 2025 · Common Stock, par value $0.000001 per share · 52.4% in May 27, 2025
Voss Capital, LP
SCHEDULE 13G/A · filed Apr 22, 2026 · Common Stock, par value $0.000001 per share · 5.3% in Dec 17, 2025
What ACTU reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Bios 2024 Co-Invest
An entity · legal entity · owns, named in the 10-K filed Mar 26, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 26, 2026.
Insider tradesForm 4
1sales
1purchases
0sales on a scheduled plan
1people selling
$1.6Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 2, 2025 to Nov 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Thomson Todd S | director | 1 | $1.6M | 0 | 0 | $0 |
| Schmitt Daniel M | President, CEO and Director | 0 | $0 | 0 | 1 | $0 |